Blueprint Medicines Co. (NASDAQ:BPMC) Shares Purchased by Barclays PLC

Barclays PLC raised its position in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 10.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 189,127 shares of the biotechnology company's stock after acquiring an additional 17,931 shares during the quarter. Barclays PLC owned approximately 0.30% of Blueprint Medicines worth $16,494,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in shares of Blueprint Medicines by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 6,774,884 shares of the biotechnology company's stock worth $590,905,000 after purchasing an additional 91,450 shares during the last quarter. Wellington Management Group LLP boosted its position in shares of Blueprint Medicines by 8.0% during the 4th quarter. Wellington Management Group LLP now owns 4,281,364 shares of the biotechnology company's stock worth $373,421,000 after acquiring an additional 316,754 shares in the last quarter. William Blair Investment Management LLC boosted its position in shares of Blueprint Medicines by 16.1% during the 4th quarter. William Blair Investment Management LLC now owns 1,944,695 shares of the biotechnology company's stock worth $169,616,000 after acquiring an additional 269,896 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Blueprint Medicines by 0.7% in the 4th quarter. Geode Capital Management LLC now owns 1,490,101 shares of the biotechnology company's stock valued at $129,996,000 after acquiring an additional 9,914 shares during the last quarter. Finally, Pictet Asset Management Holding SA raised its position in shares of Blueprint Medicines by 1.5% during the 4th quarter. Pictet Asset Management Holding SA now owns 1,183,682 shares of the biotechnology company's stock worth $103,241,000 after acquiring an additional 17,175 shares in the last quarter.

Insider Buying and Selling

In related news, COO Christina Rossi sold 2,274 shares of the business's stock in a transaction dated Monday, March 24th. The stock was sold at an average price of $95.02, for a total value of $216,075.48. Following the transaction, the chief operating officer now owns 69,266 shares in the company, valued at approximately $6,581,655.32. The trade was a 3.18 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Ariel Hurley sold 3,203 shares of Blueprint Medicines stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $92.62, for a total value of $296,661.86. Following the sale, the insider now owns 18,270 shares in the company, valued at $1,692,167.40. This represents a 14.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.21% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Needham & Company LLC reiterated a "buy" rating and issued a $133.00 price target on shares of Blueprint Medicines in a research note on Tuesday, April 8th. JMP Securities reaffirmed a "market outperform" rating and issued a $125.00 target price on shares of Blueprint Medicines in a research report on Friday, February 14th. StockNews.com cut shares of Blueprint Medicines from a "hold" rating to a "sell" rating in a research report on Monday, March 3rd. HC Wainwright reaffirmed a "buy" rating and set a $135.00 price objective on shares of Blueprint Medicines in a report on Friday, February 14th. Finally, JPMorgan Chase & Co. boosted their target price on Blueprint Medicines from $126.00 to $129.00 and gave the company an "overweight" rating in a report on Tuesday, February 4th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $124.95.

Blueprint Medicines Trading Down 0.5 %

Shares of NASDAQ:BPMC traded down $0.43 during trading on Thursday, reaching $85.38. 304,185 shares of the stock were exchanged, compared to its average volume of 767,885. The firm's 50-day moving average price is $87.82 and its 200 day moving average price is $93.12. The firm has a market cap of $5.46 billion, a price-to-earnings ratio of -79.05 and a beta of 0.75. Blueprint Medicines Co. has a 12-month low of $73.04 and a 12-month high of $121.90. The company has a debt-to-equity ratio of 1.15, a quick ratio of 2.80 and a current ratio of 2.85.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last announced its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. On average, sell-side analysts anticipate that Blueprint Medicines Co. will post -1.28 earnings per share for the current fiscal year.

Blueprint Medicines Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.